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DBT protocols has been solved by the introduction of 
synthetic mammograms (sDM) reconstructed from DBT 
datasets. Thus, whenever possible, sDM/DBT should be 
preferred to DM/DBT. However, before introducing DBT 
as a routine screening tool for average-risk women, we 
should wait for the results of randomized controlled tri-
als and for a statistically significant and clinically relevant 
reduction in the interval cancer rate, hopefully associated 
with a reduction in the advanced cancer rate. Otherwise, 
a potential for overdiagnosis and overtreatment cannot be 
Abstract This position paper, issued by ICBR/SIRM and 
GISMa, summarizes the evidence on DBT and provides 
recommendations for its use. In the screening setting, 
DBT in adjunct to digital mammography (DM) increased 
detection rate by 0.5–2.7‰ and decreased false positives 
by 0.8–3.6% compared to DM alone in observational 
and double-testing experimental studies. The reduction 
in recall rate could be less prominent in those screening 
programs which already have low recall rates with DM. 
The increase in radiation exposure associated with DM/
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excluded. Studies exploring this issue are ongoing. Screen-
ing of women at intermediate risk should follow the same 
recommendations, with particular protocols for women 
with previous BC history. In high-risk women, if mam-
mography is performed as an adjunct to MRI or in the case 
of MRI contraindications, sDM/DBT protocols are sug-
gested. Evidence exists in favor of DBT usage in women 
with clinical symptoms/signs and asymptomatic women 
with screen-detected findings recalled for work-up. The 
possibility to perform needle biopsy or localization under 
DBT guidance should be offered when DBT-only findings 
need characterization or surgery.
Keywords Breast cancer · Digital breast tomosynthesis · 
Mammography · Screening
Introduction
In the last years, many reports have appeared about digi-
tal breast tomosynthesis (DBT) in both the diagnostic 
and screening setting. In fact, thanks to a pseudo-three-
dimensional reconstruction, DBT allows for overcoming 
some limitations of standard two-dimensional (2D) digi-
tal mammography (DM) caused by structural overlapping 
and resulting into false-negative and false-positive find-
ings [1]. The X-ray tube moves along an angular direc-
tion and generates multiple low-dose variably angled pro-
jections of the compressed breast. The reconstruction of 
multiple images of thin slices of the compressed breast 
is obtained by specialized software [2, 3]. The technical 
solutions proposed by vendors differ for tube movement 
(continuous/discontinuous), width of oscillation angle, 
number of projections, type of detector, and other char-
acteristics, although no substantial effects on diagnostic 
performance related to these differences have been 
reported so far.
This position paper, issued by the Italian College of 
Breast Radiologists by the Italian Society of Medical Radi-
ology (SIRM) and the Italian Group for Mammography 
Screening (GISMa), summarizes the available evidence on 
DBT and provides practical recommendations for its use. 
For the levels of evidence (LoE) reported here, we refer 
to the definitions given by the Centre for Evidence-Based 
Medicine, Oxford, United Kingdom [4].
DBT for first‑level screening
Several studies have evaluated the potential of DBT in 
first-level screening [5–14]. In particular, three European 
prospective trials conducted in the context of organized 
population-based screening programs [6–9] and five ret-
rospective studies from spontaneous screening settings 
[10–14] have shown that DBT combined with DM (or as 
a stand-alone approach [9]) allows for a better diagnostic 
performance than DM alone.
Results of DBT differ according to the study design, the 
screening interval, and the type of screening setting (organ-
ized versus spontaneous). A review [15] reported that DBT 
provides an increase in cancer detection rate from 0.5 to 2.7 
per thousand screened women and a reduction in false-pos-
itive recall rate from 0.8 to 3.6 per 100 screened women. 
The possibility of using only the mediolateral oblique DBT 
projection, supported by one study [9], has the rationale of 
dose reduction. However, although many experiences have 
shown the superior diagnostic performance of two-view 
DBT compared with one-view DBT [16–18], the availabil-
ity of synthetic 2D mammograms generated from the DBT 
dataset (see below) has substantially overcome the problem 
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of dose. A reduction in recall rate of greatly varying mag-
nitude (from 6 to 82%, median 31%) has been found [19]. 
Notably, this variability depends on the baseline recall rate 
with standard DM because the higher the baseline DM recall 
rate, the higher the absolute and relative reduction obtained 
with DBT. Thus, the advantage of reducing the recall rate 
could be less prominent in those screening programs which 
already have low recall rates with standard DM.
If both DM and DBT are acquired (separately or with 
the so-called “combo” modality), the average glandular 
dose is approximately doubled. In fact, the DBT dose is 
similar to that of DM [20–22]. However, considering the 
dose reduction obtained through the introduction of DM 
as an alternative to film-screen mammography, the dose 
of these DM/DBT protocols too remains below the upper 
limit defined by the “European guidelines for quality 
assurance in breast cancer screening and diagnosis” pub-
lished in 2006 [23].
Of note, radiation exposure would be an issue to take 
into consideration for a generalized adoption of DM/DBT 
protocols for population-based mass screening. The solu-
tion has come from the synthetic digital mammography 
(sDM) obtained through specialized algorithms summing 
and filtering the DBT datasets. Principles and methods 
have similarities with those generating maximum intensity 
projections in computed tomography and magnetic reso-
nance imaging (MRI). These sDMs are virtual 2D mammo-
grams obtained from DBT, paying no tradeoff in terms of 
radiation exposure [24–26].
Several authors have compared sDM/DBT protocols 
with DM/DBT protocols demonstrating a similar diagnos-
tic performance [25–28]. Therefore, unless additional radi-
ation exposure is specifically justified (as in the work-up 
of suspicious findings detected at DM), a diagnostic mam-
mography examination can be performed using the sDM/
DBT approach.
Notably, two studies [29, 30] have reported that 54–57% 
of additional cancers detected by additional ultrasonogra-
phy screening after negative DM were detected by DBT. 
This is a relevant argument in favor of DBT, considering 
the practical hurdles for a generalized mass screening with 
ultrasonography in adjunct to DM.
However, in the context of organized population-based 
screening programs, a simple increase in sensitivity and 
overall diagnostic performance of a new tool, even if statis-
tically significant and clinically relevant, is not enough, per 
se, for its generalized adoption. According to the European 
Council Recommendation on cancer screening [31], evi-
dence from randomized controlled trials is needed before 
introducing new screening tools. In particular, consider-
ing the pre-existing evidence in favor of screening mam-
mography (recently confirmed by the International Agency 
for Research on Cancer [32]), caution is urged due to the 
possibility that a substantial part of the additional cancers 
detected by DBT could be overdiagnosed lesions, i.e. indo-
lent malignant lesions that would never surface clinically 
during the woman’s life [33]. Importantly, the consequence 
would be an increase in overtreatment, i.e. unnecessary sur-
gery, radiation, and/or medical therapy.
It is worth to note that most of the additional cancers 
detected with DBT have been reported to be invasive [6–
14]. A large study from the United States [10] has com-
pared DM/DBT in approximately 174,000 women with 
DM alone in approximately 281,000 women. The DM/DBT 
approach was associated with a 29% increase in detection 
rate and a 15% reduction in recall rate. All the increase 
in cancer detection was due to invasive cancers (+41%). 
No increase in the detection of ductal carcinoma in situ, 
deemed more probably overdiagnosed, was observed. 
However, we should consider that also invasive cancers can 
be indolent and overdiagnosed. Thus, no definitive conclu-
sions can be drawn.
Several other issues cannot be ignored when discuss-
ing the potential introduction of DBT for screening. They 
include at least sufficient availability of DBT equipments, 
management of suspicious findings at DBT alone, and 
increased reading time [34–36], which implies the need for 
more breast radiologists involved as screening readers.
Thus, before introducing DBT as a first-level screening 
tool, we should wait for the results of randomized con-
trolled trials (some of which are already ongoing in Italy) 
comparing a population sample having DM/DBT or sDM/
DBT at the first round and DM alone at the subsequent 
round with a population sample having DM alone at both 
rounds [37]. This will enable us to determine:
1. whether the expected increase in cancer detection at 
first round with DBT is associated or not associated 
with a reduction in interval cancer incidence;
2. whether the total incidence of advanced cancers (stage 
≥T2) in the whole study period (i.e. considering all 
cancers detected in the first or second round as well as 
interval cancers) is lower in the DBT group compared 
with the control group; and
3. whether the total incidence of breast cancer in the DBT 
group exceeds that of the control group.
The attention paid to interval cancer rate is explained 
by the possibility to use this measure as a proxy of effec-
tiveness in mortality reduction [15]. To our knowledge, 
only two articles [38, 39] have reported results concern-
ing the interval cancer rate of DBT screening. The study 
design was a single-center retrospective analysis [38] and 
a multicenter [39] prospective cohort study. Comparing 
DM alone with DM/DBT screening, a reduction in inter-
val cancer rate was observed in both studies, from 0.7 to 
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0.5 per thousand screened women [38] and from 0.6 to 
0.46 per thousand screened women [39], respectively. 
These variations were not statistically significant. How-
ever, it should be noted that neither study was designed 
and powered for interval cancer analysis, and that both 
were conducted in a spontaneous screening setting. These 
heavy limitations prevent us to draw any conclusion to be 
extrapolated to European organized biennial screening 
programs.
DBT for work‑up of screen‑detected suspicious 
findings, as a first‑line diagnostic examination 
in symptomatic women, for preoperative staging, 
and targeted evaluation after MRI
Several studies [40–48] have shown that DBT is at least 
equivalent to additional DM views (magnification, spot 
compression, 90° views, etc.), also reducing radiation 
exposure in both the diagnostic and screening setting. In 
symptomatic women, diagnostic accuracy is improved by 
DBT, reducing the number of suspicious findings and of 
unnecessary biopsies [43, 45, 46]. In the presence of palpa-
ble lesions, DBT has been reported to be never worse, and 
often better, than DM for estimating tumor size [49]. The 
better diagnostic performance of DBT is confirmed also in 
the case of invasive lobular cancers, as shown by a recent 
study [50]. In the preoperative setting, the combination of 
DM, DBT, and ultrasonography could provide the same 
information as MRI [51]. Finally, DBT allows for identify-
ing some findings additionally found on preoperative MRI 
also when they are not visible at targeted ultrasonography, 
permitting a reduction in the number of MR-guided biop-
sies [52].
Studies evaluating inter-reader variability for DM/DBT 
versus DM alone have reported for each reader an increase 
in the detection rate and a reduction in the recall rate with 
an overall increase in the diagnostic performance [53–56]. 
In the particular context of spontaneous screening, DBT 
has also been found to reduce the number of short-time 
repeat examinations [55].
All these results allow for recommending DBT for 
symptomatic women and for work-up of screen-detected 
suspicious findings.
Recommendations
Recommendations are presented here for five categories of 
women:
1. asymptomatic women at average risk (first level of 
organized or spontaneous screening);
2. asymptomatic women at intermediate risk, including 
women with a previous breast cancer;
3. symptomatic women and women needing work-up of 
screen-detected suspicious findings;
4. asymptomatic women at hereditary/familial high risk;
5. asymptomatic women at high risk due to previous 
chest radiotherapy.
A sixth, final recommendation concerns needle biopsy 
under DBT guidance.
1. Asymptomatic women at average risk (first level of 
organized or spontaneous screening)
These women should undergo DM starting not before 
the age of 40, with a screening interval that may vary 
according to local health authority’s decision. As recently 
stated by the European Society of Breast Imaging [57, 
58], direct DM should be preferred to film-screen mam-
mography due to a reduced radiation exposure [59] and 
an at least equivalent diagnostic performance [60] (LoE 
A). The preference is also in favor of DM when com-
pared with indirect digital phosphor storage plate (so-
called computer radiography) [61].
DBT can be used as a first-level screening tool in 
women at average risk:
a) in the context of studies approved by an Ethical 
Committee, with enrollment after informed consent 
signature by the woman (for randomized controlled 
trials, refer to the scheme proposed by the Osservato-
rio Nazionale Screening [37]);
b) in the well-defined context of centers being part of 
public population-based screening programs, with 
previous experience with ethically approved stud-
ies concerning at least feasibility of screening DBT, 
demonstrated through articles published in peer-
reviewed journals.
In both cases, the sDM/DBT approach should be pre-
ferred (Loe A). In both cases, centers are requested to 
provide data regarding the screening process, service, and 
impact, including the women’s compliance. Considering 
the data management needs, the necessary interactions 
with information technology services, and the impact of 
DBT on the whole multidisciplinary team, studies should 
be performed under umbrella of breast units. Moreover, 
usual monitoring data should be collected, in particular 
absolute and/or proportional incidence of interval cancer 
and of screen-detected cancers of stage T2 or higher [37, 
62, 63]. Attention should be paid to avoid that the imple-
mentation of DBT studies causes a reduction in screening 
coverage, compliance, or quality indicators.
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2. Asymptomatic women at intermediate risk, including 
those with a previous breast cancer
Up to now, no substantial evidence has been produced 
in favor or against the use of DBT for screening women 
at intermediate risk of breast cancer, i.e. those with a life-
time risk from 15 to 19%, estimated using multifactorial 
models. All these women should undergo screening DM 
with the same protocols recommended for asymptomatic 
women at average risk.
For asymptomatic women with a previous history of 
breast cancer (included in this general category of women 
at intermediate risk), we refer to the recommendations 
provided by the GISMa and the Italian College of Breast 
Radiologists by SIRM [64]. The recent observation of a 
reduction in indeterminate findings in surveillance after 
breast cancer treatment [65] plays in favor of DBT usage 
(LoE D) in this setting, with a preference for sDM/DBT 
protocols.
DBT can be used as a screening tool in women at 
intermediate risk:
a) in the context of studies approved by an Ethical Com-
mittee, with enrollment after informed consent signa-
ture by the woman;
b) in the well-defined context of centers having previous 
experience with ethically approved studies concerning 
DBT, demonstrated through articles published in peer-
reviewed journals.
Usual performance indicators should be collected, in 
particular absolute and/or proportional incidence of inter-
val cancer and of screen-detected cancers of stage T2 or 
higher [36, 61, 62].
3. Symptomatic women and women needing work-up of 
screen-detected suspicious findings
We include in this category both women with suspi-
cious clinical symptoms or signs (asking for a mammo-
gram usually ordered by a general practitioner or a spe-
cialist) and asymptomatic women with screen-detected 
suspicious findings recalled for work-up in the context of 
spontaneous or organized screening. Women with previ-
ous history of breast cancer, if having suspicious clinical 
symptoms/signs or after a suspicious finding on an imag-
ing study, are also included in this category.
In these women, if an indication to mammography 
exists and DBT is available, DBT should be performed 
(LoE A), preferably with a sDM/DBT protocol (LoE B). 
If sDM mammograms are not available, DBT can be per-
formed after DM (LoE B).
4. Asymptomatic women at hereditary/familial high risk
Women at hereditary/familial high risk should be 
screened in the context of dedicated pathways [66–71]. 
Considering the higher radiosensitivity of their breast tis-
sue and the high sensitivity of MRI for breast cancer, mam-
mography can be avoided at least up to 35 years of age, in 
particular in BRCA1 mutation carriers. If mammography 
is performed as an adjunct to MRI or in the case of MRI 
contraindications, a sDM/DBT protocol is suggested (LoE 
D). In all cases of mammographic work-up, DBT should be 
preferred to additional DM projections (LoE D).
5. Asymptomatic women at high risk due to previous 
chest radiotherapy
Recommendations regarding breast cancer screening for 
these women (mainly lymphoma survivors) were recently 
provided by the Italian College of Breast Radiologists by 
SIRM [72]. Both DM and contrast-enhanced MRI should 
be performed annually due to the suboptimal sensitivity of 
each of the two techniques [73–76]. A sDM/DBT protocol 
could be preferred to DM alone (LoE D).
6. Needle biopsy under DBT guidance
DBT can show doubtful/suspicious findings without any 
clinical correlate and even undetectable on DM, sDM, or 
ultrasonography [5–8]. This may occur in both the screen-
ing and diagnostic settings. In those cases, when the DBT 
finding is neither detectable at targeted ultrasonography 
nor at DM review, a needle biopsy (and, when necessary, 
also presurgical localization) should be performed under 
DBT guidance. Importantly, DBT guidance offers impor-
tant advantages in terms of shorter procedure duration and 
reduced radiation exposure [77, 78] (LoE B).
As a consequence, centers offering DBT should also 
offer DBT-guided interventions for DBT findings not oth-
erwise identifiable. These interventions can be performed 
at the same center where DBT was done or at another 
center functionally connected with the first one. At present, 
in fact, few centers are equipped with the device for DBT-
guided interventions.
Conclusions
Evidence available for DBT allows to recommend its usage 
for all cases of symptomatic women and women needing 
work-up of screen-detected suspicious findings (consider-
ing both spontaneous and organized screening). In these 
settings, when available, sDM/DBT protocols should be 
preferred for symptomatic women.
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Breast cancer screening using the current mammogra-
phy technology has been demonstrated to be effective in 
reducing mortality from the disease. From this perspective, 
completing the shift from analog film-screen mammog-
raphy and computed radiography systems, that are still in 
use, to direct digital mammography systems ranks first in 
the order of priorities.
A generalized adoption of DBT as a first-level screen-
ing tool should wait for a specific evidence, in particular for 
a statistically significant and clinically relevant reduction 
in interval cancer rate (hopefully associated with a reduc-
tion in advanced cancer rates). When this evidence will be 
available, both asymptomatic women at average and inter-
mediate risk (including those with a previous breast can-
cer history) will be allowed to be screened with DBT on 
a routine basis. Accurate data collection will be necessary 
for many years in order to assess the overall impact of DBT 
technology in terms of mortality reduction and other effi-
cacy/effectiveness indicators. For high-risk women, when a 
mammogram is indicated, a sDM/DBT protocol should be 
preferred.
The already existing evidence, which has been built with 
a non-negligible contribution of Italian breast radiologists, 
plays in favor of DBT. A trend for making DBT the mam-
mography of the next future can be outlined. However, 
even in the United States, where FDA approved the use of 
some DBT devices in some cases for screening, the use of 
DBT is still quite limited. A recent survey [79] among the 
members of the Society of Breast Imaging reported that of 
670 responders, only 200 (30%) use DBT although 62% of 
non-users have planned to equip themselves with DBT.
Studies and researches are still needed for a deeper eval-
uation of DBT, a relevant innovation in breast imaging. In 
particular, the risk of an increased overdiagnosis and also 
several organizational issues (including increased reading 
time) suggest to wait for a more conclusive evidence before 
adopting DBT in population-based screening, a position 
shared with other experts and medical or health authority 
bodies worldwide [15, 57, 58, 80, 81].
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